Acceleron Announces Retirement of Director Jean George
07 Abril 2020 - 3:05PM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company
dedicated to the discovery, development, and commercialization of
TGF-beta superfamily therapeutics to treat serious and rare
diseases, today announced that Jean George is retiring from her
position on its Board of Directors.
“As one of Acceleron’s longest-serving Board members, Jean has
been instrumental in helping to guide the Company toward its
current position of strength,” said Francois Nader, MD, Chairman of
Acceleron Pharma. “Acceleron has benefited significantly from her
extensive industry, investment, and entrepreneurial experience. The
Board and I are enormously grateful for her myriad contributions
over the years.”
Ms. George has been a member of Acceleron’s Board of Directors
since 2005. Since 2002, she has been a Managing Director at
Advanced Technology Ventures (ATV) and serves as the firm’s East
Coast lead partner for healthcare investments. Since 2013, she has
also served as a Managing Director at LSV Capital Management. Prior
to joining ATV, Ms. George was a Director at BancBoston Ventures,
where she led the team’s investment activity in multiple health
care portfolio holdings. Prior to transitioning to venture
investing, she spent 10 years at Genzyme Corporation, where she
held a variety of operational roles, including Vice President of
Global Sales and Marketing and served as a Vice President and
Founder of Genzyme’s Tissue Repair Division.
“I have been fortunate to work alongside Jean throughout my
three and a half-year tenure as CEO,” said Habib Dable, President
and Chief Executive Officer of Acceleron. “I am grateful for her
invaluable industry insights, investor acumen, and strong
scientific instincts. I know I speak for the entire senior
management team in thanking Jean for her guidance and support over
the last 15 years.”
“It’s been a professional thrill to participate in Acceleron’s
maturation from a research-focused organization to a clinical-stage
company to a commercial enterprise with an impressive portfolio,”
said Ms. George. “I know I am leaving the Company poised for growth
in capable hands. Given Acceleron’s more recent achievements in
hematology and pulmonary, I am excited to watch the next chapters
unfold.”
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. Acceleron’s leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in
hematologic and pulmonary diseases. In hematology, Acceleron and
its global collaboration partner, Bristol-Myers Squibb, are
co-promoting newly approved REBLOZYL® (luspatercept-aamt), the
first and only approved erythroid maturation agent, in the United
States and are developing luspatercept for the treatment of chronic
anemia in myelofibrosis. Acceleron is developing sotatercept for
the treatment of pulmonary arterial hypertension, having recently
reported positive topline results of the Phase 2 PULSAR trial and
actively enrolling patients in the Phase 2 SPECTRA trial.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on social media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200407005688/en/
Acceleron Pharma Inc. Investors: Todd James, IRC, (617) 649-9393
Senior Vice President, Corporate Affairs and Investor Relations
Media: Matt Fearer, (617) 301-9557 Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024